Profile

New User

New to Graphy Publications? Create an account to get started today.

Registered Users

Have an account? Sign in now.

How to Cite | Author Information | Publication History | Funding Information
International Journal of Psychology & Behavior Analysis Volume 7 (2021), Article ID 7:IJPBA-172, 4 pages
https://doi.org/10.15344/2455-3867/2021/172
Research Article
Anxiolytic Medication and Long Acting Injectable Antipsychotics (LAI) in Schizophrenia: A Post-hoc Analysis of a 3-year Prospective Cohort Study

Carla Spínola1, Daniel Neto2,*, Leonor Santana3 and Joaquim Gago4

1Psychiatrist, Serviço de Psiquiatria do Serviço de Saúde da Região Autónoma da Madeira, Portugal
2Psychiatrist, Casa de Saúde São João de Deus, Funchal, Portugal
3Psychiatry Resident, Centro Hospitalar de Lisboa Ocidental, EPE, Portugal
4Senior Psychiatrist Consultant, Centro Hospitalar de Lisboa Ocidental, EPE, Portugal
Dr Daniel Neto, Psychiatrist, Casa de Saúde São João de Deus, Funchal, Portugal; E-mail: danielcarvalhoneto@gmail.com
22 January 2021; 25 February 2021; 27 February 2021
Spínola C, Neto D, Santana L, Gago J (2021) Anxiolytic Medication and Long Acting Injectable Antipsychotics (LAI) in Schizophrenia: A Post-hoc Analysis of a 3-year Prospective Cohort Study. Int J Psychol Behav Anal 7: 172. doi: https://doi.org/10.15344/2455-3867/2021/172
The authors declare that Carla Spínola was funded by the European Economic Area Grants to make part of the data collection of the patients, for an economical analyses published elsewhere [12].
© 2021 Spínola et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

  1. Zohar J, Stahl S, Moller HJ, Blier P, Kupfer D, et al. (2015) A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol 25: 2318-2325. [CrossRef] [Google Scholar] [PubMed]
  2. American Psychiatric Association (2013) Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition.
  3. Pelayo-Terán JM, Gajardo Galán VG, de la Ortiz-García de la Foz V, Martínez-García O, Tabarés-Seisdedos R, et al. Rates and predictors of relapse in first-episode non-affective psychosis: a 3-year longitudinal study in a specialized intervention program (PAFIP). Eur Arch Psychiatry Clin Neurosci 267: 315-323. [CrossRef] [Google Scholar] [PubMed]
  4. Heres S, Lambert M, Vauth R (2014) Treatment of early episode in patients with schizophrenia: the role of long acting antipsychotics. Eur Psychiatry 29: 1409-1413. [CrossRef] [Google Scholar] [PubMed]
  5. Braga R, Mendlowicz M, Marrocos R (2005) Anxiety disorders in outpatients with schizophrenia: prevalence and impact on the subjective quality of life. J Psychiatr Res 39: 409-414. [CrossRef] [Google Scholar] [PubMed]
  6. Huppert JD, Weiss KA, Lim R, Pratt S, Smith TE, et al. (2001) Quality of life in schizophrenia: Contributions of anxiety and depression. Schizophr Res 51: 171-180. [CrossRef] [Google Scholar] [PubMed]
  7. Chakos MH, Glick ID, Miller AL, Hamner MB, Miller DD, et al. (2006) Special Section on CATIE Baseline Data: Baseline Use of Concomitant Psychotropic Medications to Treat Schizophrenia in the CATIE Trial. Psychiatr Serv 57: 1094-1101. [CrossRef] [Google Scholar]
  8. Chakos M, Patel J, Rosenheck R, Glick I, Hamner M, et al. (2011) Concomitant Psychotropic Medication Use During Treatment of Schizophrenia Patients: Longitudinal Results from the CATIE Study. Clin Schizophr Relat Psychoses 5: 124-134. [CrossRef] [Google Scholar] [PubMed]
  9. Ritsner MS, Gibel A (2006) The effectiveness and predictors of response to antipsychotic agents to treat impaired quality of life in schizophrenia: A 12-month naturalistic follow-up study with implications for confounding factors, antidepressants, anxiolytics, and mood stabilizers. Prog Neuropsychopharmacol Biol Psychiatry 30: 1442-1452. [CrossRef] [Google Scholar] [PubMed]
  10. Rubio JM, Correll CU (2017) Reduced all-cause mortality with antipsychotics and antidepressants compared to increased all-cause mortality with benzodiazepines in patients with schizophrenia observed in naturalistic treatment settings. Evid Based Ment Health 20: e6. [CrossRef] [Google Scholar] [PubMed]
  11. Fond G, Berna F, Boyer L, Godin O, Brunel L, et al. (2018) Benzodiazepine long-term administration is associated with impaired attention/working memory in schizophrenia: results from the national multicentre FACE-SZ data set. Eur Arch Psychiatry Clin Neurosci 268: 17-26. [CrossRef] [Google Scholar] [PubMed]
  12. Matias MA, Chaves P, Pereira ME, Spinola C, Gago J, et al. (2017) Treatment Costs of Severe Mental Disorders in Portugal. J Ment Health Policy Econ.
Best viewed in Mozilla Firefox, Google Chrome, Safari, Above IE 9.0 version
Privacy Policy | Copyright & Permissions
Copyright © 2013-2024 Graphy Publications, All Rights Reserved.